VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)
VRDN-001-303
Phase 3 small_molecule active
Quick answer
VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor) for Thyroid eye disease is a Phase 3 program (small_molecule) at Viridian Pharma Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Viridian Pharma Ltd
- Indication
- Thyroid eye disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active